Author:

Keywords:

Administration, Oral, Adolescent, Adult, Brain, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Encephalitis, Female, Gadolinium, Humans, Immunosuppressive Agents, International Cooperation, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Outcome Assessment (Health Care), Propylene Glycols, Sphingosine, Time Factors, Young Adult, Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, PLACEBO-CONTROLLED TRIAL, BRAIN ATROPHY, CEREBRAL ATROPHY, ORAL FINGOLIMOD, FTY720 FINGOLIMOD, RELAPSING MS, INTERFERON, DISABILITY, IMPAIRMENT, LESIONS, Fingolimod Hydrochloride, Outcome Assessment, Health Care, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group, 1103 Clinical Sciences, 1109 Neurosciences, 1702 Cognitive Sciences, Neurology & Neurosurgery, 3202 Clinical sciences, 3209 Neurosciences

Abstract:

To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study.